Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01441-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Daniele Cattaneo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 28 consecutive patients admitted to our hospital between September 2011 and November 2021 for idiopathic hypereosinophilia (HE). Bone marrow (BM) morphology was evaluated in 22 patients: while in six subjects BM was unremarkable, in the remaining cases an increase in BM eosinophils was observed, together with a slight increase in BM fibrosis (MF-1) in 5/22 patients. A total of 4/28 patients had at least one genetic lesion by targeted NGS. In particular, the genes involved were: two each of TET2 and DNMT3A ; and one each of JAK2 V617F, ASXL1 , PPM1D , and ZBTB33 . Notably, JAK2 V617F and TET2 mutations co-occurred, with the JAK2 V617F-mutated sample also carrying TET2 lesions. Median VAF was 21%, with the exception of the oncodriver JAK2 V617F, which showed a VAF > 50% in the reported case. Of note, of the four cases bearing lesions, 2/4 had multiple hits in different genes. While in recent years mutational analysis using NGS has proven to be able to differentiate clonal hematopoietic neoplasms from reactive processes in diagnostically difficult cases, we found somatic mutations in only 14.3% of patients who acceded to our hospital for idiopathic HE. More importantly, excluding the JAK2 V617F-mutated case with an underlying MPN-Eo diagnosis, NGS was able to identify somatic mutations in only three cases, all older than 70 years. Consequently, the detection of these mutations in idiopathic HE patients should be interpreted with caution and only in the context of other supportive clinical-pathological findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Division of Pathology, ASST Santi Paolo E Carlo, Milan, Italy.
- Department of Health Sciences, University of Milan, Milan, Italy.
- Hematology Division, Myeloproliferative Syndromes Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milano, Italy. alessandra.iurlo@policlinico.mi.it.
Zitieren
APA
Cattaneo, D., Marchetti, A., Bucelli, C., Galli, N., Lionetti, M., Bellani, V., Gianelli, U., Passamonti, F., Bolli, N., & Iurlo, A. (2024). Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01441-w
Vancouver
Cattaneo D, Marchetti A, Bucelli C, Galli N, Lionetti M, Bellani V, et al. Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01441-w
BibTeX
@article{Cattaneo2024,
author = {Cattaneo, Daniele and Marchetti, Alfredo and Bucelli, Cristina and Galli, Nicole and Lionetti, Marta and Bellani, Valentina and Gianelli, Umberto and Passamonti, Francesco and Bolli, Niccolò and Iurlo, Alessandra},
title = {Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01441-w}
}
EUVIMED